Pharmaceutical industry vendor Kalderos has asked a federal court to vacate a federal health agency’s policy prohibiting drug manufacturers from conditioning 340B drug discounts on covered entities’ submission of drug claims data.
Kalderos has created a service called 340B Pay to let drug companies provide 340B pricing as a post-purchase rebate rather than as price discount. 340B provider groups say this method of providing 340B pricing is illegal and are fighting against it. In November 2020, a bipartisan group of 217 U.S. representatives asked then-U.S. Health and Human Services Secretary Alex Azar to stop Kalderos and drug companies from changing 340B from a discount to a rebate program.
Pharmaceutical industry vendor Kalderos has asked a federal court to vacate a federal health agency’s policy prohibiting drug manufacturers from conditioning 340B drug discounts on covered entities’ submission of drug claims data.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
